Ask AI
ProCE Banner Activity

Decera: 約束、落とし穴、そして道筋:アルツハイマー病治療における血液バイオマーカーに関するグローバルな視点

Clinical Thought

世界中のアルツハイマー病専門家が、血液バイオマーカーについて、世界各地での臨床現場への導入状況や、医療システム全体における診断経路への将来的な位置づけの可能性などを含め、それぞれの見解を述べています。

Released: June 05, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for global primary care physicians, general practitioners, general neurologists, nurse practitioners, physician associates, and other healthcare professionals caring for patients at risk of developing Alzheimer’s Disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Decera: アルツハイマー病治療の全過程において、バイオマーカー検査に関するエビデンスに基づいた戦略と臨床ガイドラインを適用し、臨床上の意思決定と紹介を適切に行います。

Disclosure

Primary Author

Atsushi Iwata, MD, PhD: consultant/advisor/speaker: Biogen, Eisai, Fujirebio, Janssen, Kowa, Lilly, MSD, Otsuka, Sony, Sysmex, UCB.

Sebastian Palmqvist, MD, PhD: consultant/advisor/speaker: BioArctic, Danaher, Eisai, Lilly, Novo Nordisk, Roche, Sanofi.

Jiong Shi, MD, PhD, FAAN, has no relevant financial relationships to disclose.

Raymond Scott Turner, PhD, MD, FANA, FAAN: researcher (paid to institution): Cognition Therapeutics, Eisai, Lilly; consultant/advisor/speaker: Lilly.